Tagged: Food and Drug Administration (FDA)

FDA Funds UCSF-Stanford CERSI

The U.S. Food and Drug Administration has awarded the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (UCSF-Stanford CERSI) a five-year grant with up to $25 million in funding.

The Right Dose: How pharmacy researchers are making medicine more precise

Reprinted courtesy of UCSF Magazine.

In the pediatric bone marrow transplant clinic, pharmacist Janel Boyle’s past and present collide.

She drifts past young patients—many of them infants and toddlers—and notes their beaming smiles and balding heads. Her gaze shifts to the parents, their expressions tense but hopeful.

Major funding for The Kidney Project from NIBIB Quantum Program

The research journey toward building a fully functioning, surgically implantable artificial kidney as an alternative to kidney transplant and dialysis just took another step forward with the announcement of a $6 million grant to The Kidney Project, headquartered at the UCSF School of Pharmacy. The funding comes from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), one of the National Institutes of Health (NIH).

FDA launches UCSF-Stanford center for innovation in drug development, regulation

The U.S. Food and Drug Administration (FDA) is tapping the UCSF School of Pharmacy and Stanford University to launch its first West Coast regulatory science center, focused on spurring innovation in the development and evaluation of safer and more effective medications.

The UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) has been formally launched with an initial FDA grant of $3.3 million.

Feature articles shine spotlight on Kidney Project

The San Francisco Chronicle and the Bay Area News Group, which includes the San Jose Mercury News and Oakland Tribune, have published feature articles this week focused on The Kidney Project, an effort to develop the first implantable bioartificial kidney to treat end-stage renal disease.

Self care group supports researching non-prescription access by patients to urgent and chronic care drugs

On March 22 and 23, 2012, the U.S. Food and Drug Administration (FDA) held a public hearing to explore the idea of switching some medications to treat chronic conditions and health emergencies from prescription to over- and behind-the-counter status. Representing a group of academic health professionals, called The Self Care Collaborative, R.

William Soller defines the roadmap for Rx-to-OTC switches

If you are a pharmaceutical company seeking to switch your prescription medication to one sold directly to consumers—as an over-the-counter or OTC drug—William Soller, PhD, has your road map.

UCSF study: Drug information resources may miss parts of boxed warnings

An analysis by UCSF faculty members from the Schools of Pharmacy and Medicine has found that the half-dozen most reputable electronic drug information resources—tools commonly used by clinicians to make prescription and patient monitoring decisions—may not provide key elements of some medications’ black box warnings.

Pages